羟苯磺酸钙治疗慢性马兜铃酸肾病实验研究和临床观察_郭伟.pdfVIP

当代医学　2009年2月第15卷第6期总第161期　Contemporary Medicine, Feb. 2009,Vol.15 No.6 Issue No.161 羟苯磺酸钙治疗慢性马兜铃酸肾病实验研究和临床观察 郭伟 冯江敏 李小姝 [摘要] 目的 观察羟苯磺酸钙对慢性马兜铃酸肾病（CAAN）的治疗作用，探讨该药对肾脏的保护机制，初步评价其治疗CAAN的应用价值。方 法 动物实验部分：制备慢性马兜铃酸肾病大鼠模型，随机分为未治疗组和治疗组，另设正常对照组。观察治疗4周后大鼠肾功能及肾组织病理改 变。临床观察部分：将48例患者随机分为两组，观察组26例，在常规综合治疗基础上加用羟苯磺酸钙胶囊0.5g，日三次，口服；对照组22例采用常 规综合治疗观察两组间相关指标的变化。结果 动物实验部分：与未治疗组比较，治疗组肾功明显改善，肾间质纤维化减轻。临床观察部分：与对 P 照组比较，观察组24小时尿蛋白定量、尿素氮和血肌酐均明显降低（“ ＜0.05”）。结论 羟苯磺酸钙能延缓肾间质纤维化的进展，改善肾脏功 能，在CAAN的治疗方面有一定应用价值。 [关键词] 羟苯磺酸钙；马兜铃酸 [Abstract] Objective To observe the effects of calcium dobesilate on arisolochic acid nephrapathy(AAN) and to explore the probable mechanism of calcium dobesilate improving microcirculation of kidney with AAN. Methods Forty-eight patients of AAN were randomly divided into two groups. Twenty-six cases in the observed group received calcium dobesilate(0.5g, three times a day) plus routine methods, but the other Twenty- 床临与物药 two cases in the control group only received routine methods.the model of AAN was infused into stomachs with Caulis aristolochia manshuriensis in SD rats.Rats were divided into two groups: NX group and the calcium dobesilate therapy group,and set the SHAM group Results Urinary protein, serum creatinine and BUN had been decreased significantly in both groups, but more significantly in calcium dobesilate treated group.In animal experiment,the renal function and pathological change of remnant kidney in the treatment group were significantly improve as compare with NX group. Conclusion calcium dobesilate can protect renal function by improving pathological change of CAAN. [Key words] Arisolochic acid nephrapathy; calcium dobesilate M e d i c a t 马兜铃酸肾病（Arisolochic acid